1. Home
  2. ERAS vs BOC Comparison

ERAS vs BOC Comparison

Compare ERAS & BOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • BOC
  • Stock Information
  • Founded
  • ERAS 2018
  • BOC 2009
  • Country
  • ERAS United States
  • BOC United States
  • Employees
  • ERAS N/A
  • BOC N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • BOC
  • Sector
  • ERAS Health Care
  • BOC
  • Exchange
  • ERAS Nasdaq
  • BOC Nasdaq
  • Market Cap
  • ERAS 432.6M
  • BOC 448.1M
  • IPO Year
  • ERAS 2021
  • BOC 2017
  • Fundamental
  • Price
  • ERAS $1.16
  • BOC $14.73
  • Analyst Decision
  • ERAS Strong Buy
  • BOC Buy
  • Analyst Count
  • ERAS 6
  • BOC 3
  • Target Price
  • ERAS $4.83
  • BOC $19.00
  • AVG Volume (30 Days)
  • ERAS 2.3M
  • BOC 198.8K
  • Earning Date
  • ERAS 05-07-2025
  • BOC 05-13-2025
  • Dividend Yield
  • ERAS N/A
  • BOC N/A
  • EPS Growth
  • ERAS N/A
  • BOC N/A
  • EPS
  • ERAS N/A
  • BOC N/A
  • Revenue
  • ERAS N/A
  • BOC $108,274,901.00
  • Revenue This Year
  • ERAS N/A
  • BOC $9.66
  • Revenue Next Year
  • ERAS N/A
  • BOC $6.33
  • P/E Ratio
  • ERAS N/A
  • BOC N/A
  • Revenue Growth
  • ERAS N/A
  • BOC 12.49
  • 52 Week Low
  • ERAS $1.01
  • BOC $12.41
  • 52 Week High
  • ERAS $3.45
  • BOC $16.29
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 41.47
  • BOC 57.39
  • Support Level
  • ERAS $1.01
  • BOC $13.29
  • Resistance Level
  • ERAS $1.29
  • BOC $14.57
  • Average True Range (ATR)
  • ERAS 0.17
  • BOC 0.57
  • MACD
  • ERAS 0.00
  • BOC 0.05
  • Stochastic Oscillator
  • ERAS 31.25
  • BOC 95.36

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About BOC Boston Omaha Corporation

Boston Omaha Corp is a us-based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. They generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

Share on Social Networks: